Side Effects Dampen Neurologists' Enthusiasm For Novel MS Drugs

With nearly a dozen new multiple sclerosis drugs in some phase of mid- to late-stage development – from the first oral options to infrequently administered biologics – the treatment paradigm for the debilitating disease appears on the cusp of significant change.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet